⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ntrk1

Every month we try and update this database with for ntrk1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)NCT02568267
Breast Cancer
Cholangiocarcin...
Colorectal Canc...
Head and Neck N...
Lymphoma, Large...
Melanoma
Neuroendocrine ...
Non-Small Cell ...
Ovarian Cancer
Pancreatic Canc...
Papillary Thyro...
Primary Brain T...
Renal Cell Carc...
Sarcomas
Salivary Gland ...
Adult Solid Tum...
Entrectinib
18 Years - Hoffmann-La Roche
Merestinib In Non-Small Cell Lung Cancer And Solid TumorsNCT02920996
Carcinoma, Non-...
Solid Tumor
Merestinib
18 Years - Dana-Farber Cancer Institute
Merestinib In Non-Small Cell Lung Cancer And Solid TumorsNCT02920996
Carcinoma, Non-...
Solid Tumor
Merestinib
18 Years - Dana-Farber Cancer Institute
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat CancerNCT02122913
Solid Tumors Ha...
Larotrectinib (...
18 Years - Bayer
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene FusionNCT03025360
Tumors Harborin...
Larotrectinib (...
- Bayer
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid TumorsNCT03182257
Solid Tumor
ONO-7579
18 Years - Ono Pharmaceutical Co. Ltd
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsNCT02650401
Solid Tumors
CNS Tumors
Entrectinib
0 Years - 18 YearsHoffmann-La Roche
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsNCT02576431
Solid Tumors Ha...
BAY2757556 (Lar...
18 Years - Bayer
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat CancerNCT03215511
Solid Tumors Ha...
Selitrectinib (...
1 Month - Bayer
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene FusionNCT03206931
Solid Tumors Ha...
Selitrectinib (...
1 Month - Bayer
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsNCT02650401
Solid Tumors
CNS Tumors
Entrectinib
0 Years - 18 YearsHoffmann-La Roche
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid TumorsNCT03182257
Solid Tumor
ONO-7579
18 Years - Ono Pharmaceutical Co. Ltd
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: